Skip to content
The Nexus
DossierENTITY

ORIGIN 3

Coverage of ORIGIN 3 in the Nexus archive.

Earliest in view: Jul 7 · 20:51 UTCMost recent: Jul 7 · 20:51 UTC
Co-mentioned in this coverage
atacicepttopic1Trutaknatopic1FDAorganization1IgA nephropathytopic1
Recent coverage
  • HEALTHJul 7 · 20:51 UTCMEDPAGE TODAY
    First-in-Class Drug Approved for IgA Nephropathy

    The FDA granted accelerated approval to atacicept (Trutakna) for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression. Approval was supported by data from the ORIGIN 3 trial for the once-weekly self-administered drug.

ORIGIN 3 · Dossier · The Nexus